Clene Inc. entered into a subaward amendment with New York University on October 15, 2026, securing funding of up to $7.2 million for the fourth year of an NIH Grant supporting an Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis. The agreement covers the period from September 1, 2026, to August 31, 2027. Clene Inc. is a biotechnology company focused on developing therapies for neurological diseases.
